March 28, 2023 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision-making in the EP lab, is proud to announce the achievement of significant milestones demonstrating both the clinical and commercial success of the ECGenius System.¹

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that the company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV

March 27, 2023 — Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces cardiovascular deaths, strokes, and other adverse outcomes by 20% compared to usual care.

March 24, 2023 — Abbott announced new data that found monitoring patients remotely with hemodynamic pressure sensing technology, such as with its CardioMEMS HF System, can significantly1 improve survival in heart failure patients with reduced ejection fraction (HFrEF).

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of immunotherapeutic vaccines, has announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401.